What Are Drusen and How Can Valeda Help?
Why Talk About Drusen?
Drusen are tiny deposits that form beneath the retina as we age. On their own, a few small drusen can be normal in healthy people over 50. But when drusen become numerous or larger (soft)—especially near the macula—they are a hallmark of early and intermediate dry AMD and a key predictor of progression to vision‑impacting disease. Understanding your drusen type and load, and tracking them precisely over time, is central to modern AMD care.
At Peter Ivins Eye Care in Bearsden, we’ve built Scotland’s most advanced, patient‑centred pathway for drusen and early AMD—combining ZEISS CLARUS 500 true‑colour ultra‑widefield imaging, ZEISS CIRRUS 6000 OCT/OCT‑Angiography with FastTrac, multimodal analysis in ZEISS Retina Workplace, and AI support (including Altris AI). Clinical leadership from Craig McArthur—international lecturer, journal contributor and founder of Scotland’s first macular screening clinic (2008)—ensures you receive expert interpretation and tailored advice.
What Exactly Are Drusen?
Drusen are yellowish deposits made of lipids and proteins that accumulate between the retinal pigment epithelium (RPE) and Bruch’s membrane. They vary by size, edges, and location:
- Hard drusen: small, well‑defined; relatively common with ageing; lower risk when few and peripheral.
- Soft drusen: larger, with fuzzy edges and a tendency to cluster; associated with higher risk of AMD progression and, in some cases, conversion to wet AMD.
- Reticular pseudodrusen (RPD) (sub‑retinal drusenoid deposits): sit above the RPE, often linked with a greater risk profile and reduced dark adaptation.
Key point: You can have drusen with no symptoms. Their number, size, type and distribution—not just their presence—drive risk and management.
Why Drusen Matter in AMD
Drusen accumulation reflects metabolic stress in the macula. In early AMD, drusen and pigment changes may subtly reduce contrast sensitivity or night vision. As risk rises, two late outcomes are possible:
- Geographic atrophy (GA) – progressive loss of RPE and photoreceptors in patches (advanced dry AMD)
- Wet (neovascular) AMD – fragile new vessels grow under the macula and leak
Accurately staging AMD using drusen characteristics helps us predict risk and personalise your plan (monitoring intervals, imaging, nutrition, and suitability for therapies such as photobiomodulation at The Valeda Clinic).
How We Detect and Monitor Drusen (Our Technology Advantage)
1) Ultra‑widefield true‑colour imaging (ZEISS CLARUS 500)
Scotland’s first CLARUS 500 provides high‑definition, true‑colour images from the macula to the far periphery. We can show you where drusen sit, their size, and how they change over time. The CLARUS also provides blue/green fundus autofluorescence (FAF), highlighting RPE stress and early atrophy patterns important in GA monitoring.
2) High‑definition OCT with FastTrac (ZEISS CIRRUS 6000)
OCT generates cross‑sectional “slices” of the retina to measure drusen volume, identify pigment epithelial detachments (PEDs), and quantify structural change. FastTrac eye‑tracking reduces motion artefacts, delivering crisp, repeatable scans.
3) OCT‑Angiography (OCT‑A)
OCT‑A maps blood flow without dye, helping us rule in/out early macular neovascularisation if risk factors or symptoms emerge.
4) Multimodal change analysis and AI
With ZEISS Retina Workplace, we register CLARUS and CIRRUS images to the same coordinates and compare visits at a glance. Altris AI supports consistency by flagging subtle features and change trends.
This integrated stack lets us detect small but meaningful changes early—and adjust your plan promptly.
Symptoms to Watch For
Many patients with drusen notice little at first. Seek urgent assessment if you experience:
- Metamorphopsia (straight lines look wavy/kinked)
- A central smudge, grey patch or missing area
- Sudden decline in reading or face recognition
For home monitoring, we recommend the Amsler grid and simple weekly checks—one eye at a time—and to contact us immediately if anything changes.
Can Nutrition and Lifestyle Help?
Evidence supports the AREDS2 supplement (vitamin C, vitamin E, zinc, copper, lutein/zeaxanthin—without beta‑carotene for current/former smokers) in intermediate AMD to reduce the risk of progression to advanced stages. A Mediterranean‑style diet, smoking cessation, and cardiovascular risk control also matter. We’ll assess macular pigment optical density (MPOD) and advise on diet and supplementation tailored to you. Note: Supplements do not cure AMD and aren’t proven to prevent onset, but they can slow progression in the right patients. Always discuss with your clinician.
Where Does Valeda Photobiomodulation Fit?
Photobiomodulation (PBM) with the Lumithera Valeda Light Delivery System is a non‑invasive, light‑based therapy for dry AMD. It delivers specific wavelengths—590 nm (yellow), 660 nm (red), 850 nm (near‑infrared)—to support mitochondrial function, reduce oxidative stress and inflammation, and improve cellular metabolism in the retina.
What patients report and what studies suggest
Clinical programmes (e.g., LIGHTSITE) have reported improvements in visual function (including best‑corrected visual acuity and contrast sensitivity) in early/intermediate dry AMD, alongside favourable anatomical trends (such as drusen metrics) and reduced incidence of new‑onset GA in some analyses. PBM is not a cure, and results vary, but it offers a painless, drug‑free, adjunctive option to support macular health in appropriate patients.
PBM and drusen
While PBM does not “dissolve” drusen on demand, its cellular‑supportive effects may help stabilise macular function in eyes with significant drusen burden—particularly when combined with evidence‑based nutrition, meticulous imaging follow‑up, and risk‑factor control.
At The Valeda Clinic (Peter Ivins Eye Care), PBM is delivered within a structured programme with baseline and post‑treatment imaging so you—and we—can see what’s changing.
What Happens in a Valeda Course?
- Comfortable, non‑invasive light delivery via headset
- ~10 minutes per session
- Series of sessions over several weeks, with periodic boosters as advised
- No drops, needles, or downtime
Safety has been favourable in clinical trials. Suitability is assessed case‑by‑case with full imaging.
Who Is a Good Candidate at The Valeda Clinic?
You may be considered if you have:
- Early or intermediate dry AMD with soft drusen and/or RPD
- Functional complaints (e.g., reduced contrast, dim‑light difficulty) out of proportion to acuity
- Desire for a non‑invasive adjunct to evidence‑based care (AREDS2, lifestyle, monitoring)
We will not use Valeda for wet AMD—that requires urgent anti‑VEGF treatment via a retina specialist, while we co‑manage imaging.
Valeda treatment – Book Now
…we can help you understand your baseline, your risk, and your options.
📞 Call us: 0141 943 3300
📍 Visit our clinic in Bearsden, Glasgow
📅 Book a Valeda Assessment online
Learn more at www.valedascotland.co.uk
For more information about Valeda treatment visit:
FAQ’s
Are drusen the same as AMD?
No. Many people have small drusen with normal sight. Risk rises with size, number and type (especially soft drusen) and associated pigment changes.
Can drusen be removed?
There’s no “drusen removal” procedure. We focus on risk reduction, AREDS2, lifestyle, and tailored therapies such as Valeda PBM where suitable.
Do drusen always lead to wet AMD?
No. Drusen increase risk, but many patients never convert. Regular imaging (OCT/FAF/OCT‑A) is key to early detection.
How often should I be checked?
We individualise intervals (often 3–12 months), based on your drusen load, symptoms, and imaging.
Is Valeda safe?
Clinical studies report a favourable safety profile. We confirm suitability and monitor closely with advanced imaging.